monarchE: abemaciclib and adjuvant endocrine therapy for high-risk HR+ early breast cancer

Common Sense Oncology Journal Club: Breast CancerПодробнее

Dr Mouabbi on the Use of Ribociclib vs Abemaciclib in HR+/HER2– Breast CancerПодробнее

Age-stratified findings from the monarchE trial of abemaciclib in breast cancerПодробнее

MonarchE TrialПодробнее

4-year MonarchE results: increasing benefits with abemaciclib + ET for ER+/HER2- high-risk early BCПодробнее

monarchE: adjuvant abemaciclib + endocrine therapy in patients with HR+, HER2- high-risk eBCПодробнее

MonarchE 4-year: abemaciclib + endocrine therapy for HR+, HER2-, node-positive, high-risk early BCПодробнее

ESMO 2020 Expert Video Report on CDK4 6i in the adjuvant treatment of breast cancerПодробнее

monarchE: adjuvant abemaciclib in HR+ breast cancerПодробнее

MonarchE results: Abemaciclib plus endocrine therapy in high-risk early breast cancerПодробнее

MonarchE: investigating adjuvant abemacicilib for high-risk HR+ breast cancerПодробнее

Adjuvant CDK4 and 6 Inhibition to Prevent Recurrences in High-Risk HR+/HER2- Early Breast CancerПодробнее

Highlights from SABCS 2020: New data on CDK4/6 inhibitors, omitting chemotherapy and radiotherapyПодробнее